Company attributes
Other attributes
Amylin Pharmaceuticals, Inc. is a biopharmaceutical company that engages in discovering, developing and commercializing drug candidates for the treatment of diabetes and other metabolic disorders. The company currently has exclusive rights to two drug candidates in late-stage development for the treatment of diabetes, the SYMLIN™ (pramlintide acetate) and AC2993 (synthetic exendin-4).
The company invented and patented SYMLIN many years ago, and it acquired the rights that relate to AC2993 via an exclusive patent license from Dr. John Eng, has filed patent applications covering developments in AC2993 and uses what resulted from its own internal research and development.
The company has a third drug candidate, AC3056, which is in early-stage clinical trials, and maintains a focused research and development program to discover and in-license other drug candidates for metabolic diseases.
People at Amylin are discovering, developing, and marketing innovative therapies with life-changing potential to the people who are struggling with diabetes and obesity.
